Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Dermatitis, Dermatitis contact, Feeling hot, Pruritus
Clinical narrative: contact dermatitis; getting warmer; face swelled; flaring up more; flaring up more; itchy face; face swelled, was itchy and scaly; rash on face/patch on back/severe condition on face; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 2022SA210622.  A 62-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPIXENT), since 17May2022 (Batch/Lot number: unknown) at 300 mg (300 mg, qow (every other week)), subcutaneous for dermatitis atopic. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DERMATITIS CONTACT (non-serious), outcome "unknown", described as "contact dermatitis"; FEELING HOT (non-serious), outcome "unknown", described as "getting warmer"; SWELLING FACE (non-serious), outcome "unknown", described as "face swelled"; CONDITION AGGRAVATED (non-serious), DERMATITIS (non-serious), outcome "unknown" and all described as "flaring up more"; PRURITUS (non-serious), outcome "unknown", described as "itchy face"; SKIN EXFOLIATION (non-serious), outcome "unknown", described as "face swelled, was itchy and scaly"; RASH (non-serious), outcome "unknown", described as "rash on face/patch on back/severe condition on face". The action taken for dupilumab was unknown. Therapeutic measures were taken as a result of dermatitis contact, swelling face, condition aggravated, dermatitis, pruritus, rash.  Additional information: It was unknown if the patient had any medical history, concomitant dose or risk factor. It was unknown if there were lab data results available. The patient had contact dermatitis, getting warmer, face swelled and flaring up more while being treated with DUPILUMAB (DUPIXENT and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE). On 17May2022, the patient started taking DUPIXENT (DUPILUMAB) strength 150mg/mi at dose 300 mg QOW (every other week) subcutaneous (with an unknown formulation, batch number, expiry date) for atopic dermatitis, unspecified. On an unknown date, the patient developed a non-serious events contact dermatitis, getting warmer, face swelled, itchy face and scaly, rash on face patch on back severe condition on face, flaring up more (unknown latency) following the first dose intake of DUPILUMAB and TOZINAMERAN. It was reported that maintenance dose done 5/17. Rash on face the day after receiving Pfizer COVID boosters getting warmer, flaring up more. The patient cut the grass (the day before starting medication and wife said he looked like a burn victim. The patient's face swelled, was itchy and scaly. The patient reported that patch on back was not as bad. Severe condition on face. Wearing a mask irritated it a bit. The patient stated, did the injection in his thigh it was easier to do than the stomach. The patient had ointment for flares, patient said he had contact dermatitis, however medical info stated diagnosis was atopic dermatitis. It was unknown if the patient experienced any additional symptoms of events. Medication details and reason for taking the medicine: suspect; dupixent 300 mg/2 pen 2s dose: I pen (300 mg) under the skin frequency: every 14 days. The patient was treated with Triamcinolone.  Follow-up attempts are completed. No further information is expected.